U.S. markets closed
  • S&P Futures

    4,431.50
    -1.50 (-0.03%)
     
  • Dow Futures

    34,760.00
    +17.00 (+0.05%)
     
  • Nasdaq Futures

    15,173.25
    -21.50 (-0.14%)
     
  • Russell 2000 Futures

    2,277.20
    +0.20 (+0.01%)
     
  • Crude Oil

    75.57
    +0.12 (+0.16%)
     
  • Gold

    1,753.50
    +1.50 (+0.09%)
     
  • Silver

    22.67
    -0.02 (-0.11%)
     
  • EUR/USD

    1.1696
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.4840
    +0.0240 (+1.64%)
     
  • Vix

    18.76
    +1.01 (+5.69%)
     
  • GBP/USD

    1.3701
    -0.0003 (-0.02%)
     
  • USD/JPY

    111.0600
    +0.0820 (+0.07%)
     
  • BTC-USD

    42,548.67
    -1,715.76 (-3.88%)
     
  • CMC Crypto 200

    1,054.46
    -47.06 (-4.27%)
     
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • Nikkei 225

    30,025.92
    -214.14 (-0.71%)
     

How Many Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Outlook Therapeutics, Inc. (NASDAQ:OTLK) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.

With a market capitalization of US$391m, Outlook Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about Outlook Therapeutics.

Check out our latest analysis for Outlook Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Outlook Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Outlook Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Outlook Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Outlook Therapeutics is not owned by hedge funds. GMS Tenshi Holdings Pte. Limited is currently the largest shareholder, with 29% of shares outstanding. With 11% and 6.8% of the shares outstanding respectively, Syntone Technologies Group Co. Ltd. and GMS Ventures & Investments are the second and third largest shareholders.

Our research also brought to light the fact that roughly 51% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Outlook Therapeutics

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in Outlook Therapeutics, Inc.. In their own names, insiders own US$5.3m worth of stock in the US$391m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 43% ownership, the general public have some degree of sway over Outlook Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With an ownership of 6.8%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Private Company Ownership

It seems that Private Companies own 41%, of the Outlook Therapeutics stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Outlook Therapeutics better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for Outlook Therapeutics you should be aware of, and 1 of them makes us a bit uncomfortable.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.